Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]


Trilaciclib dihydrochloride

A CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression
Catalog #: B3120
SKU-Size Size Price Qty
B3120-5 5 mg
B3120-25 25 mg
More Sizes Get Quote

Product Details

Alternate Name G1T28 dihydrochloride; 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one;dihydrochloride
Appearance Solid
CAS # 1977495-97-8
Molecular Formula C₂₄H₃₂Cl₂N₈O
Molecular Weight 519.5
Purity ≥ 97%
InChi InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
PubChem CID 124081865
MDL Number MFCD31630829
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


Trilaciclib dihydrochloride is a CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression. It induces a G1 cell-cycle arrest in CDK4/6-dependent HS68 cells with an EC₅₀ of 30 nM. It is used to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.